Open access
Jul 2026
Isoalantolactone inhibits pancreatic ductal adenocarcinoma progression via direct targeting of NLRP3-mediated inflammation-angiogenesis axis
IATL functions as a novel NLRP3 pathway inhibitor, suppressing angiogenesis through anti-inflammatory mechanisms, thereby effectively inhibiting PDAC progression and suggesting that IATL holds potential as a therapeutic agent for pancreatic cancer.
Ying Zhang, Changquan Liu, Shengjiang Liu et al.
· Frontiers in Pharmacology · 0 citations